维生素D结合蛋白在糖尿病肾脏病中的作用机制探讨

doi:10.3969/j.issn.1004-583X.2022.06.018

摘要/Abstract

摘要：

糖尿病肾脏病是糖尿病重要并发症,发病机制复杂,包括糖脂代谢紊乱、血流动力学异常、氧化应激反应等。巨噬细胞浸润是糖尿病肾脏病的特征性表现。维生素D结合蛋白(VDBP)是血浆维生素D及其代谢产物最主要的转运蛋白,可转化为强效巨噬细胞活化因子(MAF)发挥炎性作用。尿VDBP为糖尿病肾脏病的早期诊断标志物,其作用机制有待深入探讨。研究发现,VDBP基因多态性与糖尿病临床特征相关;VDBP通过调控维生素D代谢影响胰岛素抵抗;VDBP结合血游离脂肪酸,诱导β细胞功能异常,介导氧化应激等炎症反应,损害肾小管和肾小球从而促进肾脏疾病进展。糖尿病肾脏病血清和尿VDBP浓度增加,维生素D生物利用度降低,补充维生素D及类似物可显著降低尿蛋白,具有临床应用价值。现就VDBP在糖尿病肾脏病的相关机制进行综述。

中图分类号:

R977.6

孙妍, 高玉叶, 高硕. 维生素D结合蛋白在糖尿病肾脏病中的作用机制探讨[J]. 临床荟萃, 2022, 37(6): 568-571.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.06.018

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I6/568

参考文献 32

[1]	Giuseppe P, Giuseppe P, Andrea N, et al. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”[J]. J Nephrol, 2020, 33(1):9-35. doi: 10.1007/s40620-019-00650-x pmid: 31576500
[2]	Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities[J]. Clin J Am Soc Nephrol, 2017, 12(12):2032-2045. doi: 10.2215/CJN.11491116 URL
[3]	Ritz E, Zeng XX, Rychlík I. Clinical manifestation and natural history of diabetic nephropathy[J]. Contrib Nephrol, 2011, 170:19-27.
[4]	Chaykovska L, Heunisch F, von Einem G, et al. Urinary vitamin d binding protein and KIM-1 are potent new biomarkers of major adverse renal events in patients undergoing coronary angiography[J]. PLoS One, 2016, 11(1):e0145723. doi: 10.1371/journal.pone.0145723 URL
[5]	Shoukry A, Bdeer Sel-A, El-Sokkary RH, et al. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus[J]. Mol Cell Biochem, 2015, 408(1-2):25-35. doi: 10.1007/s11010-015-2479-y pmid: 26104579
[6]	Turkes GF, Uysal S, Demir T, et al. Associations between bioavailable vitamin d and remnant cholesterol in patients with type 2 diabetes mellitus[J]. Cureus, 2021, 13(2):e13248.
[7]	Rozmus D, Płomiński J, Augustyn K, et al. rs7041 and rs4588 polymorphisms in vitamin D binding protein gene (VDBP) and the risk of diseases[J]. Int J Mol Sci, 2022, 23(2):933. doi: 10.3390/ijms23020933 URL
[8]	Eisa NH, Khodir AE, El-Sherbiny M, et al. Phenethyl isothiocyanate attenuates diabetic nephropathy via modulation of glycative/oxidative/inflammatory signaling in diabetic rats[J]. Biomed Pharmacother, 2021, 142:111666. doi: 10.1016/j.biopha.2021.111666 URL
[9]	Fu Y, Sun Y, Wang M, et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism[J]. Cell Metab, 2020, 32(6):1052-1062. doi: 10.1016/j.cmet.2020.10.019 URL
[10]	Yoshibayashi M, Kume S, Yasuda-Yamahara M, et al. Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes[J]. Biochem Biophys Res Commun, 2020, 525(2):319-325. doi: 10.1016/j.bbrc.2020.02.088 URL
[11]	Fawzy MS, Beladi FIA. Association of circulating vitamin D, VDBP, and vitamin D receptor expression with severity of diabetic nephropathy in a group of saudi type 2 diabetes mellitus patients[J]. Clin Lab, 2018, 64(10):1623-1633.
[12]	Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: The ADVANCE Study[J]. Diabetes, 2014, 63(3):1115-23. doi: 10.2337/db12-1625 URL
[13]	María-Castro A, Concha MDL, Pantoja-Meléndez CA. Low-grade inflammation and its relation to obesity and chronic degenerative diseases[J]. Revista Médica Del Hospital General De México, 2016, 80(2):101-105. doi: 10.1016/j.hgmx.2016.06.011 URL
[14]	Fawzy MS, Beladi FIA. Association of circulating vitamin D, VDBP, and vitamin D receptor expression with severity of diabetic nephropathy in a group of saudi type 2 diabetes mellitus patients[J]. Clin Lab, 2018, 64(10):1623-1633.
[15]	Bai X, Luo Q, Tan K, et al. Diagnostic value of VDBP and miR-155-5p in diabetic nephropathy and the correlation with urinary microalbumin[J]. Exp Ther Med, 2020, 20(5):86. doi: 10.3892/etm.2020.9214 pmid: 32968443
[16]	Fawzy MS, Beladi FIA. Association of circulating vitamin D, VDBP, and vitamin D receptor expression with severity of diabetic nephropathy in a group of saudi type 2 diabetes mellitus patients[J]. Clin Lab, 2018, 64(10):1623-1633.
[17]	Fawzy MS, Abu AlSel BT. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 saudi diabetic patients[J]. J Diabetes Res, 2018, 8517929.
[18]	Hirai M, Suzuki S, Hinokio Y, et al. Variations in vitamin D-binding protein (group-specific component protein) are associated with fasting plasma insulin levels in Japanese with normal glucose tolerance[J]. J Clin Endocrinol Metab, 2000, 85(5):1951-1953.
[19]	Lunyera J, Davenport CA, Pendergast J, et al. Modifiers of plasma 25-hydroxyvitamin d and chronic kidney disease outcomes in black americans: The jackson heart study[J]. J Clin Endocrinol Metab, 2019, 104(6):2267-2276. doi: 10.1210/jc.2018-01747 pmid: 30668751
[20]	Corica D, Zusi C, Olivieri F, et al. Vitamin D affects insulin sensitivity and β-cell function in obese non-diabetic youths[J]. Eur J Endocrinol, 2019, 181(4):439-450. doi: 10.1530/EJE-19-0369 URL
[21]	Al Ghadeer HA, AlRamadan MS, Al Amer MM, et al. Vitamin D serum levels in type 2 diabetic patients: A cross-sectional study[J]. Cureus, 2022, 14(2):e22558.
[22]	Ashraf AP, Huisingh C, Alvarez JA, et al. Insulin resistance indices are inversely associated with vitamin D binding protein concentrations[J]. J Clin Endocrinol Metab, 2014, 99(1):178-183. doi: 10.1210/jc.2013-2452 URL
[23]	Li C, Su F, Liang Z, et al. Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression[J]. Mol Immunol, 2022, 144:16-25. doi: 10.1016/j.molimm.2022.02.008 URL
[24]	Cantero-Navarro E, Rayego-Mateos S, Orejudo M, et al. Role of macrophages and related cytokines in kidney disease[J]. Front Med (Lausanne), 2021, 8:688060.
[25]	Nishikawa T, Edelstein D, Brownlee M. The missing link: A single unifying mechanism for diabetic complications[J]. Kidney Int Suppl, 2000, 77:S26-S30.
[26]	Jiang WJ, Xu CT, Du CL, et al. Tubular epithelial cell-to-macrophage communication forms anegative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy[J]. Theranostics, 2022, 12(1):324-339. doi: 10.7150/thno.63735 URL
[27]	Ma L, Wu F, Shao Q, et al. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway[J]. Drug Des Devel Ther, 2021, 15:3207-3221. doi: 10.2147/DDDT.S319260 URL
[28]	Fawzy MS, Abu AlSel BT. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 saudi diabetic patients[J]. J Diabetes Res, 2018: 8517929.
[29]	Fowlkes JL, Bunn RC, Cockrell GE, et al. Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetes[J]. Exp Diabetes Res, 2011, 269378.
[30]	Gharib AF, Askary AE, Almehmadi M, et al. Vitamin D and hypoxia-inducible factor (HIF-1α) serum levels as markers for progression of nephropathy in type 2 diabetic patients[J]. Clin Lab, 2022, 68(4):10.7754.
[31]	Pastukhova Y, Luzza F, Shevel S, et al. Changes in metabolic parameters in patients with diabetic kidney disease depending on the status of D3[J]. Rev Recent Clin Trials, 2022.
[32]	Shi L, Xiao C, Zhang Y, et al. Vitamin D/vitamin D receptor/Atg16L1 axis maintains podocyte autophagy and survival in diabetic kidney disease[J]. Ren Fail, 2022, 44(1):694-705. doi: 10.1080/0886022X.2022.2063744 URL

维生素D结合蛋白在糖尿病肾脏病中的作用机制探讨

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕莎莎, 宋金兰, 石健. m.3243A>G突变相关线粒体糖尿病1例并文献复习[J]. 临床荟萃, 2024, 39(2): 160-163.
[2]	张佳楠, 孙琳琳, 詹潇燕, 李冰. 血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系[J]. 临床荟萃, 2024, 39(1): 34-37.
[3]	位增, 曹灵, 佘敦敏, 刘彦, 王艳, 张真稳. 54例2型糖尿病患者合并新型冠状病毒感染的死亡原因分析[J]. 临床荟萃, 2023, 38(9): 806-812.
[4]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[5]	杨鑫, 许华娇. 基于Web of Science糖尿病患者心理干预研究的文献计量学分析[J]. 临床荟萃, 2023, 38(8): 731-736.
[6]	马光宇, 罗慧娟, 王冬菊, 肖小敏. 黄芩苷治疗糖尿病及其并发症的研究进展[J]. 临床荟萃, 2023, 38(8): 757-762.
[7]	张欣欣, 刘国庆, 王蓓蓓. 糖尿病酮症酸中毒引起极度血小板增多症1例并文献复习[J]. 临床荟萃, 2023, 38(8): 719-721.
[8]	金家辉, 杨阳, 秦铜, 何雨欣, 苏美华. 补充益生菌对2型糖尿病患者糖代谢改善的meta分析[J]. 临床荟萃, 2023, 38(7): 581-587.
[9]	贾丽娜, 吴美妮, 尹昌浩. 2型糖尿病认知功能障碍发病机制的研究进展[J]. 临床荟萃, 2023, 38(6): 554-558.
[10]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[11]	苏晨蓓, 王富军. 糖尿病下肢动脉疾病介入治疗疗效的研究进展[J]. 临床荟萃, 2023, 38(6): 569-572.
[12]	吴亚楠, 延天美, 梁鹏, 魏立民. 中老年糖尿病患者抑郁症状的高危识别[J]. 临床荟萃, 2023, 38(6): 516-520.
[13]	吕丽丽, 翟满满, 丁小艳, 陈永清. 线粒体转录因子A介导的线粒体功能障碍在糖尿病心肌病中的作用[J]. 临床荟萃, 2023, 38(5): 465-468.
[14]	易静静, 圈启芳, 马婕. 调节小胶质细胞反应性:糖尿病视网膜病变新见解[J]. 临床荟萃, 2023, 38(4): 364-368.
[15]	杨旻星, 孙璐, 叶赟, 徐文东, 黄小琳, 张海云, 徐英蕾. 中青年2型糖尿病合并阻塞性睡眠呼吸暂停低通气综合征患者认知功能特点及其影响因素[J]. 临床荟萃, 2023, 38(3): 216-220.